



**PARTICIPANT STATISTICS**

**SECOND QUADRIMESTER 2011**

**HIV MARKERS**

**anti-HIV-1 or 1/2 Screening**

Method	Specimen 1			Specimen 2			Specimen 3			Specimen 4			Specimen 5		
	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos	Neg	Ind	Pos
Abbott Architect HIV Ag/Ab			5			5	5					5	5		
Abbott HIV-1/HIV-2 rDNA EIA			3			3	3					3	3		
Bio-Rad Genscreen HIV-1/2		1	4		1	4	5				1	4	5		
Bio-Rad HIV-1/2 Plus O EIA	1		37	1		37	38			1		37	37		
Bio-Rad MultiSpot			4			4	4					4	4		
Clearview Complete HIV 1/2			17	1		16	16		1	1		16	16		1
Clearview Stat-Pak	2		128		2	128	130			2		128	129	1	
J&J Vitros ECi HIV 1/2			3			3	3					3	3		
MedMira Reveal			3			3	3					3	3		
OraQuick Advance HIV 1/2	1	1	40		1	41	41		1		1	41	42		
OraQuick Rapid HIV-1/2			6			6	6					6	6		
Siemens Advia			8			8	8					8	7		
Trinity Uni-Gold Recombigen			31			31	31					31	31		
<b>Total Population</b>	<b>4</b>	<b>3</b>	<b>298</b>	<b>2</b>	<b>5</b>	<b>298</b>	<b>303</b>		<b>2</b>	<b>4</b>	<b>3</b>	<b>298</b>	<b>301</b>	<b>1</b>	<b>1</b>
<b>Flagging</b>	*****			*****				*****	*****	*****				*****	*****

**anti-HIV-1 or 1/2**

**Confirmation**

Method	Specimen 1			Specimen 2			Specimen 3			Specimen 4			Specimen 5		
	Neg	Neg, TNP	Pos	Neg	Neg, TNP	Pos	Neg	Neg, TNP	Pos	Neg	Neg, TNP	Pos	Neg	Neg, TNP	Pos
BioRad/Genetic Sys HIV-1 WB			18			18	10	8				18	10	8	
Cam Biotech HIV-1 Westrn Bl			2			2	2					2	2		
Confirmation by repeat testing			19			19	19					19	19		
Waldheim Fluorognost IFA			6			6	5	1				6	5	1	
<b>Total Population</b>	<b>0</b>	<b>0</b>	<b>45</b>	<b>0</b>	<b>0</b>	<b>45</b>	<b>36</b>	<b>9</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>45</b>	<b>36</b>	<b>9</b>	<b>0</b>
<b>Flagging</b>	*****	*****		*****	*****				*****	*****	*****				*****

Correct responses are defined as those reflecting agreement among 80% or more of all participants or referees. Unacceptable responses are indicated by "\*\*\*\*\*" on the Flagging line of each specimen.